Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05063981Completed

Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma

Role: collaborator

NCT05941234Not ApplicableRecruiting

Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma

Role: collaborator

NCT06321172Not ApplicableCompleted

Muscle and Bone Changes After 6 Months of FES Cycling

Role: collaborator

NCT06292897Recruiting

Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression

Role: collaborator

NCT05887310Unknown

In Vitro Modeling of Drug-resistant Psychiatric Disorders Using Induced Pluripotent Cells

Role: collaborator

All 5 trials loaded